Organization
Cardior Pharmaceuticals
2 clinical trials
Clinical trial
Phase 2, Multicenter, Randomized, Parallel, 3-arm, Placebo-controlled Study to Assess Efficacy and Safety of CDR132L in Patients With Reduced Left Ventricular Ejection Fraction (≤ 45%) After Myocardial InfarctionStatus: Active (not recruiting), Estimated PCD: 2024-09-04
Clinical trial
Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Safety and Efficacy Study of CDR132L on Reverse Cardiac Remodeling in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction and Cardiac HypertrophyStatus: Not yet recruiting, Estimated PCD: 2025-09-01